“Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons >/=18 Years Old”, J Infect Dis, vol. 212, pp. 552-561, 2015.
, “Immunogenicity of Avian Influenza A/Anhui/01/2005(H5N1) Vaccine with MF59 Adjuvant: A Randomized Clinical Trial”, JAMA, vol. 312, pp. 1420-1428, 2014.
, “HSV-1 and HSV-2 Seroprevalence in the United States Among Asymptomatic Women Unaware of any Herpes Simplex Virus Infection (Herpevac Trial for Women)”, Southern Medical Journal, vol. 107, pp. 79-84, 2014.
, “Epidemiology, Clinical Presentation, and Antibody Response to Primary Infection With Herpes Simplex Virus Type 1 and Type 2 in Young Women”, Clin Infect Dis, vol. 56, pp. 344-351, 2013.
, “DNA Priming for Seasonal Influenza Vaccine: a Phase 1b Double-Blind Randomized Clinical Trial”, PLoS One, vol. 10, p. e0125914, 2015.
, “Correlate of Immune Protection Against HSV-1 Genital Disease in Vaccinated Women”, J Infect Dis, vol. 209, pp. 828-836, 2014.
, “VRC 702: A Multicenter Phase 1 Study of Seasonal Influenza DNA Vaccine Prime Followed by the Trivalent Inactivated Vaccine (TIV) Compared to TIV-TIV in Children and Adolescents Ages 6-17 Years”, in 2014 Annual Conference on Vaccine Research, Bethesda, MD, 2014.
, “Avian Influenza A/H7N9 Vaccine Mixed with MF59 Adjuvant at the Point-of-Use. A Randomized Clinical Trial of a Pandemic Threat Response.”, in ID Week 2014, Philadelphia, PA, 2014.
,